GDRX — GoodRx Holdings, Inc.
NASDAQ
Q1 2026 Earnings Call Summary
May 8, 2026
GoodRx Q1 2026 Earnings Call Summary
1. Key Financial Results and Metrics
- Revenue: $194 million, with a year-over-year decline in prescription transactions revenue of 24% to $113.7 million.
- Adjusted EBITDA: $58.3 million, representing a margin of 30%.
- Pharma Direct Revenue: Grew 82% year-over-year to $52.2 million, driven by strong manufacturer partnerships and successful GLP-1 launches.
- Subscription Revenue: Increased 16% year-over-year to $24.4 million, supported by condition-specific offerings.
- Monthly Active Consumers (MAC): Flat at 5.3 million quarter-over-quarter, indicating stable engagement.
2. Strategic Updates and Business Highlights
- Pharma Direct: Continues to be a key growth engine, with over 125 self-pay programs live. GoodRx accounted for approximately one-third of all Wegovy Pill transactions in the first two months post-launch.
- Rx Marketplace: Steady performance with operational execution in line with expectations. E-commerce capabilities expanded significantly.
- Subscriptions: Growth driven by GoodRx for weight loss, with plans to further integrate offerings into employer channels.
- Partnerships: Collaboration with Viatris and Pfizer to enhance access and affordability for various medications.
3. Forward Guidance and Outlook
- 2026 Revenue Guidance: Raised to $765 million - $785 million, with adjusted EBITDA expected to be at least $235 million.
- Pharma Direct Growth: Anticipated to exceed 50% year-over-year.
- Subscription Growth: Expected to build throughout the year as condition-specific programs scale.
4. Challenges and Points of Concern
- Prescription Transactions Revenue: Continued pressure expected throughout 2026, with a decline in unit economics impacting this segment.
- Market Dynamics: Increased competition in the GLP-1 space and changes in the healthcare environment, including rising uninsured rates and Medicaid eligibility changes, could pose risks.
- Surescripts Partnership: No material impact observed since its announcement, indicating potential delays in realizing benefits from this collaboration.
5. Notable Q&A Insights
- Marketing Spend: GoodRx plans to increase marketing investment in condition-specific subscriptions, having previously reduced overall marketing spend.
- Pharma Direct vs. Prescription Transactions: Management acknowledged potential cannibalization of prescription transactions revenue by Pharma Direct, which is viewed positively as a more durable revenue stream.
- Weather Impact: Minor impact from weather-related disruptions noted, with volumes typically recovering in subsequent weeks.
- Competitive Landscape: GoodRx remains confident in its position, citing strong brand recognition and a broad retail network as key differentiators against competitors in the GLP-1 market.
Overall, GoodRx demonstrated strong performance in Q1 2026, particularly in Pharma Direct and subscriptions, while facing ongoing challenges in prescription transactions revenue and competitive pressures in the market. The company remains optimistic about future growth driven by strategic initiatives and partnerships.